SR604
Hemophilia A and B (with/without inhibitors), Factor VII Deficiency
Phase 1Active
Key Facts
Indication
Hemophilia A and B (with/without inhibitors), Factor VII Deficiency
Phase
Phase 1
Status
Active
Company
About Equilibra Bioscience
Equilibra Bioscience is a private, clinical-stage biotech advancing SR604, a novel anti-APC monoclonal antibody, as a potential treatment for hemophilia and other bleeding disorders. The company has initiated a Phase 1 clinical trial (NCT06349473) following U.S. FDA IND clearance and has secured Orphan Drug Designation for SR604 in hemophilia A and B. Its approach aims to rebalance the coagulation cascade by inhibiting the natural anticoagulant protein APC, offering a new mechanism of action for patients, including those with inhibitors.
View full company profile